etal|中国COPD患者存在新的“高风险”集群( 二 )


CVS集群的最高死亡风险值得关注 , 先前数据表明 , COPD并发心血管疾病的治疗不足[7] 。 一些研究报道了COPD并发糖尿病的死亡率增加[8-9] 。 然而 , 此研究中 , 与“高风险” CVS和 Ex-TB “集群”相比 , 糖尿病集群的预后更好 。 LCHR集群中目前吸烟者的比例较高 , LCLR集群中既往吸烟者占多数 , 这说明戒烟对COPD的自然进程及预后有好处[10-11] 。
点  评
此项最大规模的多中心研究 , 使用严格的诊断标准 , 包括纵向随访以及单独评估的验证和衍生队列[12] , 但由于仅限于三级医院 , 数据难以推广到以轻症患者为主的社区;且男性占比90%以上 , 尽管这在亚洲COPD人群中具有代表性[2-3] , 但研究结果对女性患者不具普适性 。 由于招募集群的所有临床数据均在募集时进行了整理 , 有关此集群或患者的稳定性随时间的变化仍是后续值得关注的研究领域 。
参考文献
[1]Tan WC, Ng TP. COPD in Asia: where East meets West. Chest  2008;133(2):517-527
[2]Martin A, Badrick E, Mathur R, et al. Effect ofethnicity on the prevalence, severity, and management of COPD in general practice. Br J Gen Pract 2012;62(595):e76- 81
[3]Wedzicha JA, Zhong N, Ichinose M, et al. Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at ahigh risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis 2017;12:339-349
[4]Wang C, Xu J, Yang L, et al. Prevalence and risk factors of  chronic obstructive pulmonary disease in China (theChina Pulmonary Health [CPH] study): a national cross-sectional study. Lancet  2018;391(10131):1706-1717
[5]Fang L, Gao P, Bao H, et al. Chronic obstructive  pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med 2018;6(6):421-430
[6]Lopez AD, Shibuya K, Rao C, et al. Chronic  obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27(2):397-412
[7]Kubota Y, Tay WT, Asai K, et al. Chronic  obstructive pulmonary disease and beta-blocker treatment in Asian patients with heart failure.ESC Heart Fail 2018;5(2):297-305
[8]Burgel PR, Paillasseur JL, Janssens W, et al. A simple algorithm for the identification of clinical COPD phenotypes. Eur Respir J  2017;50(5)
[9]Mannino DM, Thorn D, Swensen A,et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008;32(4):962-969
[10]Godtfredsen NS, Lam TH, Hansel TT, et al. COPD- related morbidity and mortality after smoking cessation: status of the evidence. Eur Respir J 2008;32(4):844-853
[11]Anthonisen NR, Skeans MA, Wise RA, et al.The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142(4):233-239
[12]Bhatt SP, Balte PP, Schwartz JE, et al.Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and MortalityDiscriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and MortalityDiscriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA 2019;321(24):2438-2447
本 期 作 者


推荐阅读